276 related articles for article (PubMed ID: 33084183)
1. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
4. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
6. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
7. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Xia M; Guo Z; Hu Z
Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibition in Advanced Prostate Cancer.
Fenton SE; Chalmers ZR; Hussain M
Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors for prostate cancer.
Longoria O; Beije N; de Bono JS
Semin Oncol; 2024; 51(1-2):25-35. PubMed ID: 37783649
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
11. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
15. Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.
Chen YX; Tan LM; Gong JP; Huang MS; Yin JY; Zhang W; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2021 Dec; 42(12):1970-1980. PubMed ID: 33589795
[TBL] [Abstract][Full Text] [Related]
16. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
17. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
[TBL] [Abstract][Full Text] [Related]
19. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
Cimadamore A; Lopez-Beltran A; Massari F; Santoni M; Mazzucchelli R; Scarpelli M; Galosi AB; Cheng L; Montironi R
Future Oncol; 2020 Feb; 16(5):75-80. PubMed ID: 31916449
[No Abstract] [Full Text] [Related]
20. DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
Bryce AH; Sartor O; de Bono J
Eur Urol; 2020 Oct; 78(4):486-488. PubMed ID: 32636098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
